Novo Nordisk's promising obesity treatment, amycretin, demonstrated a significant 22% weight reduction in trial participants over 36 weeks, compared to a mere 2% loss from a placebo. This breakthrough ...

Novo Nordisk (NVO) shares traded sharply higher in European trading on Friday after the Danish drugmaker said amycretin, one of its novel obesity therapies, caused up to 22% of weight loss over 36 ...

Novo Nordisk shares rose sharply Friday after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their bodyweight in a clinical trial. Shares were 10 ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novo Nordisk rose as much as 13 per cent on Friday on hopes that positive trial results for a new ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s ...

Novo Nordisk's stock tumbled more than 5% ... to repeal the IRA -- primarily because he disagrees with its clean energy and climate components. If he succeeds in fulfilling this pledge, Medicare ...

Delaware’s top court will consider reviving shareholder litigation over Anaplan Inc.'s $10 billion sale to Thoma Bravo LLC, a case with the potential to overhaul the way judges view shareholder ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company. But it ...

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Lone Star Funds is selecting advisers to explore a possible sale or initial public offering of Portuguese lender Novo Banco SA, according to people familiar with the matter. The private equity ...

Denmark and its self-ruling territory of Greenland have caught the eye of Donald Trump. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site ...